바이오마커 발굴 서비스 시장 : 전략적 인사이트 및 예측(2026-2035년)

The Biomarker Discovery Services Market is forecast to grow at a CAGR of 12.6%, reaching USD 6.35 billion in 2035 from USD 2.18 billion in 2026.

The global biomarker discovery services market is experiencing robust growth, driven by the expanding precision medicine landscape and the increasing complexity of therapeutic development. Biomarker discovery services provide specialized laboratory, computational, and translational research capabilities that enable pharmaceutical companies, biotechnology organizations, academic institutions, and diagnostic developers to identify clinically meaningful biological markers. Modern biomarker discovery extends beyond laboratory experimentation by integrating genomics, proteomics, metabolomics, transcriptomics, bioinformatics, and artificial intelligence into coordinated research workflows. Internal research teams frequently encounter technological and analytical limitations because multi-omics datasets require highly specialized infrastructure and scientific expertise. Outsourcing therefore enables organizations to access advanced technologies while improving research efficiency and reducing operational complexity. Demand is increasing because precision medicine continues expanding across oncology, neurology, immunology, cardiovascular diseases, infectious diseases, and rare genetic disorders. Therapeutic development increasingly depends on biomarkers capable of improving patient stratification, disease monitoring, and clinical endpoint selection throughout drug development. Service providers continue investing in high-throughput sequencing, proteomics platforms, digital pathology, and advanced bioinformatics that improve biomarker identification while accelerating scientific validation. The strategic importance of biomarker discovery services extends beyond research into companion diagnostic development, precision therapeutics, clinical trial optimization, and personalized healthcare.

Market Drivers

Expanding Precision Medicine and Targeted Therapeutics

• Precision medicine increasingly depends on biomarkers that identify appropriate patient populations for targeted therapies, making biomarker discovery an essential component of pharmaceutical innovation. Demand is shifting toward specialized service providers because pharmaceutical companies require multidisciplinary expertise spanning molecular biology, bioinformatics, laboratory science, and translational medicine. Internal research capabilities frequently struggle to manage increasingly sophisticated multi-omics programs while maintaining scientific efficiency. Biomarker discovery organizations are expanding integrated laboratory and computational capabilities that accelerate biomarker identification while supporting clinical development. This transition strengthens long-term demand for outsourced biomarker discovery services.

Increasing Adoption of Multi-Omics Research

• Modern drug discovery increasingly integrates genomics, proteomics, transcriptomics, metabolomics, and epigenomics to improve biological understanding and therapeutic development. Demand is increasing because individual molecular datasets frequently fail to capture disease complexity, requiring integrated analytical approaches for meaningful biomarker discovery. Pharmaceutical organizations increasingly collaborate with specialized service providers possessing advanced sequencing platforms, mass spectrometry technologies, and computational biology expertise. Biomarker discovery companies continue investing in multi-omics technologies, artificial intelligence, and cloud-based analytics that strengthen scientific interpretation while reducing discovery timelines. These technological advances reinforce sustained demand across the biomarker discovery services market.

Growing Complexity of Biomarker Validation

• Biomarker development increasingly requires extensive analytical validation, clinical correlation, and statistical evaluation before supporting therapeutic development or regulatory submissions. Validation complexity continues increasing because modern biomarkers frequently involve multiple molecular pathways, large-scale genomic datasets, and sophisticated computational analysis. Pharmaceutical companies are partnering with specialized discovery organizations capable of integrating laboratory validation, bioinformatics, and translational medicine into coordinated development programs. Service providers continue strengthening scientific capabilities that improve biomarker reliability while supporting increasingly advanced precision medicine applications. This evolution supports continued expansion of outsourced biomarker discovery services.

Rising Biomarker Integration Throughout Drug Development

• Biomarkers increasingly influence target identification, patient recruitment, dose optimization, clinical endpoint selection, and post-market therapeutic monitoring throughout pharmaceutical development. Drug developers continue expanding biomarker programs because precision medicine strategies improve clinical trial efficiency and therapeutic success. Biomarker discovery therefore becomes a foundational activity throughout the pharmaceutical lifecycle rather than an isolated research function. Service providers are integrating biomarker identification, computational biology, translational research, and companion diagnostic development into comprehensive scientific programs that improve coordination between research and clinical development. This integrated research model continues strengthening market growth.

Market Restraints

• High scientific complexity associated with multi-omics analysis and biomarker validation continues increasing research costs and technical challenges. Limited availability of standardized validation methodologies across diverse biomarker platforms continues slowing clinical translation and regulatory acceptance. Protection of proprietary biological data, genomic information, and intellectual property continues influencing outsourcing decisions among pharmaceutical and biotechnology companies.

Technology and Segment Insights

By Service Type

• Biomarker Identification, Biomarker Validation, Multi-Omics Data Analysis, Bioinformatics & Data Interpretation, Sample Processing & Biobanking, Companion Biomarker Development, and Other Biomarker Discovery Services collectively define the service landscape. Biomarker identification establishes candidate molecules, while validation confirms their analytical and clinical relevance before pharmaceutical or diagnostic application. Demand is increasing for integrated service models because pharmaceutical companies seek partners capable of combining laboratory science, computational biology, and translational research within unified discovery programs. Bioinformatics, multi-omics analytics, and companion biomarker development continue becoming increasingly important as precision medicine expands across therapeutic areas.

By Biomarker Type

• Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Transcriptomic Biomarkers, Epigenetic Biomarkers, Imaging Biomarkers, and Other Biomarker Types represent the primary scientific categories supporting precision medicine. Genomic and proteomic biomarkers continue generating substantial demand because targeted therapeutics increasingly depend on molecular characterization and patient stratification. Transcriptomic, metabolomic, and epigenetic biomarkers are becoming increasingly important as multi-omics research improves understanding of disease biology and treatment response. Imaging biomarkers continue expanding across oncology, neurology, and cardiovascular research where non-invasive disease monitoring supports clinical decision-making.

By End User

• Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations (CROs), and Diagnostic Companies each represent important sources of demand. Pharmaceutical companies increasingly outsource biomarker research because precision medicine programs require specialized laboratory technologies, computational biology expertise, and translational research capabilities. Academic institutions continue collaborating with service providers to accelerate translation of scientific discoveries into clinically meaningful biomarkers. CROs increasingly integrate biomarker discovery into broader pharmaceutical development programs supporting targeted therapeutics and companion diagnostics. Diagnostic companies continue investing in biomarker discovery to strengthen next-generation diagnostic products and personalized healthcare solutions.

Competitive and Strategic Outlook

• The competitive landscape features major life science and clinical research organizations. Thermo Fisher Scientific Inc. distinguishes itself through its comprehensive portfolio of life science technologies, analytical instruments, genomics platforms, and bioinformatics capabilities. Eurofins Scientific SE distinguishes itself through one of the world's largest laboratory networks supporting genomics, proteomics, and translational research. Charles River Laboratories International, Inc. distinguishes itself through its comprehensive translational research, biomarker discovery, and preclinical development expertise. Labcorp Drug Development distinguishes itself through its integrated laboratory sciences, central laboratory services, and clinical development capabilities. IQVIA Inc. distinguishes itself through its integration of clinical research, real-world evidence, and precision medicine capabilities. Precision for Medicine distinguishes itself through its exclusive focus on precision medicine, translational research, and companion biomarker development.
• Strategic developments include increasing integration of artificial intelligence and machine learning, expansion of multi-omics platforms, and growth of translational research collaborations. Companies are forming partnerships with pharmaceutical developers, academic institutions, and biotechnology firms to accelerate biomarker validation and commercialization. Service expansions focus on next-generation sequencing, high-resolution mass spectrometry, digital pathology, and cloud-enabled bioinformatics. Companies that successfully integrate laboratory science, computational analytics, translational medicine, and regulatory expertise within scalable global platforms are expected to lead the market.

Conclusion

• The biomarker discovery services market is poised for significant growth, driven by the expansion of precision medicine, multi-omics research, and pharmaceutical investment in biomarker-guided drug development. The evolution from isolated laboratory research toward integrated scientific platforms supporting the complete precision medicine ecosystem is reshaping the market. Companies that successfully deliver comprehensive, scalable, and clinically meaningful biomarker discovery solutions are expected to lead the market. Ongoing technological innovation, regulatory support, and expanding translational research infrastructure will further accelerate adoption throughout the forecast period.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Biomarker Discovery Services Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Biomarker Discovery Workflow
• 3.8 Biomarker Validation Landscape
• 3.9 Precision Medicine and Companion Diagnostics Landscape
• 3.10 Translational Research Trends

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies
• 6.2 Service Innovation
• 6.3 Clinical Trial Analysis
• 6.4 Pipeline Analysis
• 6.5 AI Integration in Biomarker Discovery
• 6.6 Multi-Omics Integration

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Biomarker Qualification Pathways
• 7.3 Compliance Requirements

8. Biomarker Discovery Services Market Landscape Analysis

• 8.1 Analysis by Biomarker Type
• 8.2 Analysis by Technology Platform
• 8.3 Analysis by Discovery Stage
• 8.4 Analysis by Therapeutic Area
• 8.5 Analysis by Sample Type

9. Biomarker Discovery Services Market Segment Analysis (2021-2035)

• 9.1 By Service Type
  • 9.1.1 Biomarker Identification
  • 9.1.2 Biomarker Validation
  • 9.1.3 Multi-Omics Data Analysis
  • 9.1.4 Bioinformatics & Data Interpretation
  • 9.1.5 Sample Processing & Biobanking
  • 9.1.6 Companion Biomarker Development
  • 9.1.7 Other Biomarker Discovery Services
• 9.2 By Biomarker Type
  • 9.2.1 Genomic Biomarkers
  • 9.2.2 Proteomic Biomarkers
  • 9.2.3 Metabolomic Biomarkers
  • 9.2.4 Transcriptomic Biomarkers
  • 9.2.5 Epigenetic Biomarkers
  • 9.2.6 Imaging Biomarkers
  • 9.2.7 Other Biomarker Types
• 9.3 By End User
  • 9.3.1 Pharmaceutical & Biotechnology Companies
  • 9.3.2 Academic & Research Institutes
  • 9.3.3 Contract Research Organizations (CROs)
  • 9.3.4 Diagnostic Companies

10. Biomarker Discovery Services Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Biomarker Discovery Services Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 China
• 11.8 Japan
• 11.9 South Korea
• 11.10 India
• 11.11 Australia
• 11.12 Brazil
• 11.13 Saudi Arabia

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Service Launches

13. Company Profiles

• 13.1 Thermo Fisher Scientific Inc.
• 13.2 Eurofins Scientific SE
• 13.3 Charles River Laboratories International, Inc.
• 13.4 Labcorp Drug Development
• 13.5 IQVIA Inc.
• 13.6 Precision for Medicine
• 13.7 BioAgilytix Labs, LLC
• 13.8 Frontage Laboratories, Inc.
• 13.9 Medpace Holdings, Inc.
• 13.10 WuXi AppTec Co., Ltd.
• 13.11 Evotec SE
• 13.12 ICON plc
• 13.13 Q2 Solutions (IQVIA)
• 13.14 SGS SA
• 13.15 Revvity, Inc.

14. Biomarker Discovery Services Market Commercial Forecast Analysis

• 14.1 Forecast by Service Type
  • 14.1.1 Biomarker Identification
  • 14.1.2 Biomarker Validation
  • 14.1.3 Multi-Omics Data Analysis
  • 14.1.4 Companion Biomarker Development
• 14.2 Forecast by Biomarker Type
  • 14.2.1 Genomic Biomarkers
  • 14.2.2 Proteomic Biomarkers
  • 14.2.3 Transcriptomic Biomarkers
  • 14.2.4 Metabolomic Biomarkers
• 14.3 Forecast by End User
  • 14.3.1 Pharmaceutical & Biotechnology Companies
  • 14.3.2 Academic & Research Institutes
  • 14.3.3 Diagnostic Companies

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends